Table of Contents Author Guidelines Submit a Manuscript
International Journal of Alzheimer’s Disease
Volume 2017 (2017), Article ID 2438901, 6 pages
https://doi.org/10.1155/2017/2438901
Review Article

Seeking a New Paradigm for Alzheimer’s Disease: Considering the Roles of Inflammation, Blood-Brain Barrier Dysfunction, and Prion Disease

1Yampa Valley Medical Associates, Steamboat Springs, CO, USA
2University of Colorado School of Medicine, Aurora, CO, USA

Correspondence should be addressed to Mark E. McCaulley; moc.liamg@yelluaccmekram

Received 10 September 2017; Revised 24 October 2017; Accepted 2 November 2017; Published 5 December 2017

Academic Editor: Francesco Panza

Copyright © 2017 Mark E. McCaulley and Kira A. Grush. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. E. Berrios, “Alzheimer's disease: a conceptual history,” International Journal of Geriatric Psychiatry, vol. 5, no. 6, pp. 355–365, 1990. View at Publisher · View at Google Scholar · View at Scopus
  2. Alzheimer’s Association, “Alzheimer’s Disease Facts and Figures,” Alzheimer’s & Dementia, vol. 12, no. 4, 2016. View at Google Scholar
  3. M. E. McCaulley and K. A. Grush, “Alzheimer's disease: exploring the role of inflammation and implications for treatment,” International Journal of Alzheimer's Disease, vol. 2015, Article ID 515248, 10 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Scheltens, K. Blennow, M. M. Breteler et al., “Alzheimer's disease,” The Lancet, vol. 388, no. 10043, pp. 505–517, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Karran, M. Mercken, and B. D. Strooper, “The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics,” Nature Reviews Drug Discovery, vol. 10, no. 9, pp. 698–712, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Salloway, R. Sperling, N. C. Fox et al., “Two phase 3 trials of Bapineuzumab in mild-to-moderate Alzheimer's disease,” The New England Journal of Medicine, vol. 370, no. 4, pp. 322–333, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. D. K. V. Kumar, H. S. Choi, K. J. Washicosky et al., “Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer's disease,” Science Translational Medicine, vol. 8, no. 340, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. P. S. Aisen and K. L. Davis, “Inflammatory mechanisms in Alzheimer's disease: implications for therapy,” The American Journal of Psychiatry, vol. 151, no. 8, pp. 1105–1113, 1994. View at Publisher · View at Google Scholar · View at Scopus
  9. T. L. Sudduth, F. A. Schmitt, P. T. Nelson, and D. M. Wilcock, “Neuroinflammatory phenotype in early Alzheimer's disease,” Neurobiology of Aging, vol. 34, no. 4, pp. 1051–1059, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. R. A. Stelzmann, H. Norman Schnitzlein, and F. Reed Murtagh, “An english translation of alzheimer's 1907 paper, “über eine eigenartige erkankung der hirnrinde”,” Clinical Anatomy, vol. 8, no. 6, pp. 429–431, 1995. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Akiyama, S. Barger, S. Barnum et al., “Inflammation and Alzheimer's disease,” Neurobiology of Aging, vol. 21, no. 3, pp. 383–421, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. P. L. McGeer, J. Rogers, and E. G. McGeer, “Inflammation, Antiinflammatory Agents, and Alzheimer's Disease: The Last 22 Years,” Journal of Alzheimer's Disease, vol. 54, no. 3, pp. 853–857, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Gorska-Ciebiada, M. Saryusz-Wolska, A. Borkowska, M. Ciebiada, and J. Loba, “Serum soluble adhesion molecules and markers of systemic inflammation in elderly diabetic patients with mild cognitive impairment and depressive symptoms,” BioMed Research International, vol. 2015, Article ID 826180, 8 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Kazmierski, A. Banys, J. Latek et al., “Mild cognitive impairment with associated inflammatory and cortisol alterations as independent risk factor for postoperative delirium,” Dementia and Geriatric Cognitive Disorders, vol. 38, no. 1-2, pp. 65–78, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Schuitemaker, M. G. Dik, R. Veerhuis et al., “Inflammatory markers in AD and MCI patients with different biomarker profiles,” Neurobiology of Aging, vol. 30, no. 11, pp. 1885–1889, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. A. P. Hermida, W. M. McDonald, K. Steenland, and A. Levey, “The association between late-life depression, mild cognitive impairment and dementia: is inflammation the missing link?” Expert Review of Neurotherapeutics, vol. 12, no. 11, pp. 1339–1350, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. B. Misiak, J. Leszek, and A. Kiejna, “Metabolic syndrome, mild cognitive impairment and Alzheimer's disease-The emerging role of systemic low-grade inflammation and adiposity,” Brain Research Bulletin, vol. 89, no. 3-4, pp. 144–149, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Xia and B. T. Hyman, “Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease,” Journal of NeuroVirology, vol. 5, no. 1, pp. 32–41, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Veerhuis, H. M. Nielsen, and A. J. Tenner, “Complement in the brain,” Molecular Immunology, vol. 48, no. 14, pp. 1592–1603, 2011. View at Publisher · View at Google Scholar
  20. M. Etminan, S. Gill, and A. Samii, “Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies,” British Medical Journal, vol. 327, no. 7407, article 128, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. B. A. in 't Veld, A. Ruitenberg, A. Hofman et al., “Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease,” The New England Journal of Medicine, vol. 345, no. 21, pp. 1515–1521, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. B. P. Imbimbo, V. Solfrizzi, and F. Panza, “Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment?” Frontiers in Aging Neuroscience, vol. 2, article 19, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Jaturapatporn, M. G. E. K. N. Isaac, J. McCleery, and N. Tabet, “Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease,” Cochrane Database of Systematic Reviews, vol. 2, Article ID CD006378, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. J. F. Price, M. C. Stewart, I. J. Deary et al., “Low dose aspirin and cognitive function in middle aged to elderly adults: randomised controlled trial,” BMJ, vol. 337, p. a1198, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. J. H. Kang, N. Cook, J. Manson, J. E. Buring, and F. Grodstein, “Low dose aspirin and cognitive function in the women's health study cognitive cohort,” British Medical Journal, vol. 334, no. 7601, article 987, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. P. S. Aisen, K. A. Schafer, M. Grundman et al., “Effects of Rofecoxib or Naproxen vs Placebo on Alzheimer Disease Progression,” Journal of the American Medical Association, vol. 289, no. 21, article 2819, 2003. View at Publisher · View at Google Scholar
  27. J. Rogers, L. C. Kirby, S. R. Hempelman et al., “Clinical trial of indomethacin in Alzheimer's disease,” Neurology, vol. 43, no. 8, pp. 1609–1611, 1993. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Montagne, S. R. Barnes, M. D. Sweeney et al., “Blood-Brain barrier breakdown in the aging human hippocampus,” Neuron, vol. 85, no. 2, pp. 296–302, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. N. Schuff, N. Woerner, L. Boreta et al., “MRI of hippocampal volume loss in early Alzheimers disease in relation to ApoE genotype and biomarkers,” Brain, vol. 132, no. 4, pp. 1067–1077, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. H. J. van de Haar, S. Burgmans, J. F. Jansen et al., “Blood-Brain Barrier Leakage in Patients with Early Alzheimer Disease,” Radiology, vol. 281, no. 2, pp. 527–535, 2016. View at Publisher · View at Google Scholar
  31. M. A. Erickson and W. A. Banks, “BloodBrain barrier dysfunction as a cause and consequence of Alzheimer's disease,” Journal of Cerebral Blood Flow Metabolism, vol. 33, no. 10, pp. 1500–1513, 2013. View at Google Scholar
  32. S. McArthur, R. A. Loiola, E. Maggioli, M. Errede, D. Virgintino, and E. Solito, “The restorative role of annexin A1 at the blood-brain barrier,” Fluids and Barriers of the CNS, vol. 13, no. 1, article no. 17, 2016. View at Publisher · View at Google Scholar · View at Scopus
  33. R. D. Bell, E. A. Winkler, A. P. Sagare et al., “Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging,” Neuron, vol. 68, no. 3, pp. 409–427, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Kisler, A. R. Nelson, S. V. Rege et al., “Pericyte degeneration leads to neurovascular uncoupling and limits oxygen supply to brain,” Nature Neuroscience, vol. 20, no. 3, pp. 406–416, 2017. View at Publisher · View at Google Scholar · View at Scopus
  35. M. R. Halliday, S. V. Rege, and Q. Ma, “Accelerated pericyte degeneration and bloodbrain barrier breakdown in apolipoprotein E4 carriers with Alzheimers disease,” Journal of Cerebral Blood Flow & Metabolism, vol. 36, no. 1, pp. 216–227, 2016. View at Google Scholar
  36. J. Matsumoto, F. Takata, T. Machida et al., “Tumor necrosis factor-α-stimulated brain pericytes possess a unique cytokine and chemokine release profile and enhance microglial activation,” Neuroscience Letters, vol. 578, pp. 133–138, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Rustenhoven, D. Jansson, L. C. Smyth, and M. Dragunow, “Brain Pericytes As Mediators of Neuroinflammation,” Trends in Pharmacological Sciences, vol. 38, no. 3, pp. 291–304, 2017. View at Publisher · View at Google Scholar · View at Scopus
  38. C. Soto, “Transmissible proteins: expanding the prion heresy,” Cell, vol. 149, no. 5, pp. 968–977, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. A. L. Woerman, A. Aoyagi, S. Patel et al., “Tau prions from Alzheimer's disease and chronic traumatic encephalopathy patients propagate in cultured cells,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 113, no. 50, pp. E8187–E8196, 2016. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Pandya, A. Kuceyeski, and A. Raj, “The Brain's Structural Connectome Mediates the Relationship between Regional Neuroimaging Biomarkers in Alzheimer's Disease,” Journal of Alzheimer's Disease, vol. 55, no. 4, pp. 1639–1657, 2017. View at Publisher · View at Google Scholar · View at Scopus
  41. L. C. Walker, “Proteopathic Strains and the Heterogeneity of Neurodegenerative Diseases,” Annual Review of Genetics, vol. 50, pp. 329–346, 2016. View at Publisher · View at Google Scholar · View at Scopus
  42. Z. Jaunmuktane, S. Mead, M. Ellis et al., “Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy,” Nature, vol. 526, no. 7574, pp. 247–250, 2015. View at Publisher · View at Google Scholar · View at Scopus
  43. F. Clavaguera, T. Bolmont, R. A. Crowther et al., “Transmission and spreading of tauopathy in transgenic mouse brain,” Nature Cell Biology, vol. 11, no. 7, pp. 909–913, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. B. B. Holmes and M. I. Diamond, “Cellular models for the study of prions,” Cold Spring Harbor Perspectives in Medicine, vol. 7, no. 2, Article ID a024026, 2017. View at Publisher · View at Google Scholar · View at Scopus
  45. J. Burré, M. Sharma, and T. C. Südhof, “Cell Biology and Pathophysiology of α-Synuclein,” Cold Spring Harbor Perspectives in Medicine, 2017. View at Publisher · View at Google Scholar
  46. H. Khanam, A. Ali, M. Asif, and Shamsuzzaman, “Neurodegenerative diseases linked to misfolded proteins and their therapeutic approaches: a review,” European Journal of Medicinal Chemistry, vol. 124, pp. 1121–1141, 2016. View at Publisher · View at Google Scholar
  47. T. Nonaka and M. Hasegawa, “TDP-43 Prions,” Cold Spring Harbor Perspectives in Medicine, 2017. View at Publisher · View at Google Scholar
  48. A. D. Alonso, C. Beharry, C. P. Corbo, and L. S. Cohen, “Molecular mechanism of prion-like tau-induced neurodegeneration,” Alzheimer’s & Dementia, vol. 12, no. 10, pp. 1090–1097, 2016. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Kriegel, Z. Papadopoulos, and A. C. McKee, “Chronic Traumatic Encephalopathy: Is Latency in Symptom Onset Explained by Tau Propagation?” Cold Spring Harbor Perspectives in Medicine, 2017. View at Publisher · View at Google Scholar
  50. T. S. Kuhn, The Structure of Scientific Revolutions, The University of Chicago Press, Chicago, Ill, USA, 1962. View at Publisher · View at Google Scholar
  51. A. Tversky and D. Kahneman, “Judgment under uncertainty: heuristics and biases,” Science, vol. 185, no. 4157, pp. 1124–1131, 1974. View at Publisher · View at Google Scholar
  52. D. Kahneman, Thinking, Fast and Slow, Farrar, Straus and Giroux, New York, NY, USA, 2011.
  53. N. Sadeghi-Nejad, “The Lessons Of Failure: What We Can Learn From Bapineuzumab's Blowup,” 2012, https://www.forbes.com/sites/natesadeghi/2012/08/07/the-lessons-of-failure-what-we-can-learn-from-bapineuzumabs-blowup/#6cf522d9575a.
  54. K. Fiore and R. Dotinga, “Aisen: Negative Anti-Amyloid Trial Confirms Amyloid Hypothesis,” Medpage Today, 2016, http://www.medpagetoday.com/neurology/alzheimersdisease/61959.
  55. S. D. Bilbo, G. A. Wray, S. E. Perkins, and W. Parker, “Reconstitution of the human biome as the most reasonable solution for epidemics of allergic and autoimmune diseases,” Medical Hypotheses, vol. 77, no. 4, pp. 494–504, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. D. Buettner, The Blue Zones: Lessons for Living Longer from the People Who've Lived the Longest, National Geographic Society, Washington, DC, USA, 2010.
  57. S. L. Duffy, J. Lagopoulos, Z. Terpening et al., “Association of anterior cingulate glutathione with sleep apnea in older adults at-risk for dementia,” Sleep, vol. 39, no. 4, pp. 899–906, 2016. View at Publisher · View at Google Scholar · View at Scopus
  58. N. A. Kerner and S. P. Roose, “Obstructive Sleep Apnea is Linked to Depression and Cognitive Impairment: Evidence and Potential Mechanisms,” American Journal of Geriatric Psychiatry, vol. 24, no. 6, pp. 496–508, 2016. View at Publisher · View at Google Scholar · View at Scopus
  59. S. Ooms and Y.-E. Ju, “Treatment of Sleep Disorders in Dementia,” Current Treatment Options in Neurology, vol. 18, no. 9, article 40, 2016. View at Publisher · View at Google Scholar · View at Scopus